Chesnara Plc CSN

Bond markets have quietly rewritten the rulebook, with the US 30 year Treasury yield sitting around a 25 year high and reshaping what counts as a safe return. Higher risk free rates can punish stretched balance sheets, yet they can also reprice long term liabilities in interesting ways. This piece walks through three stocks exposed to that rate shock, and why their reaction to it deserves a closer look. The three stocks below are just a sample set, while the full screen on Simply Wall St...

Chesnara PLC (LSE:CSN) saw operating capital generation jump 79% to £96 million in the first half.  CEO Steve Murray also highlighted the group's 185% solvency coverage ratio and an active acquisition pipeline. Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has raised £1.3 million to push forward its CNS drug pipeline.  That includes trials for alcohol use disorder and addiction treatments. hVIVO PLC (AIM:HVO) has bought CRS Berlin to expand into dermatology and women's health trials.  The CEO says it opens up new markets and cross-selling opportunities in Germany. Gelion PLC (AIM:GELN, OTC:G

Chesnara PLC (LSE:CSN) CEO Steve Murray spoke with Proactive about first-half performance, including a 79% rise in operating capital generation to £96 million, progress integrating Chesnara Life and the outlook for further acquisitions. Murray said the strong capital generation reflected positive underlying performance, management actions like balance-sheet optimisation and reinsurance, and a significant contribution from Chesnara Life, formerly HSBC Life UK, which joined the group at the end of January. On integration, Murray said Chesnara has announced a combined UK leadership team and begun

Chesnara (LON:CSN) reported higher operating capital generation, cash remittances and adjusted operating profit for the first half of 2026, supported by the January acquisition of HSBC Life UK, now renamed Chesnara Life UK. Group Chief Executive Steve Murray said the company delivered “another very

Chesnara PLC (LSE:CSN) is still hunting for acquisitions, with its Scottish Widows Europe deal on track by year end. Reporting back for the first half of its financial year, the company said operating capital generation jumped 79% to £96 million. Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has raised £1.3 million to fund three separate treatment programmes. That includes trials targeting alcohol, and methamphetamine and cocaine use disorders. Savannah Energy PLC (AIM:SAVE) says its Uquo 13 well in Nigeria has started producing gas. It's now expecting output to top 20,000 barrels of oil equ

Chesnara (LSE:CSN) CEO Steve Murray says two major acquisitions have transformed the group's scale, with around £1 billion in expected lifetime cash flows. He's relaxed about market volatility and says the balance sheet could support another deal similar in size to Scottish Widows Europe. Itaconix (AIM:ITX, OTCQB:ITXXF, FRA:18G0) CEO John Shaw says revenues hit $10.5 million last year, up 61%, and he's targeting $25 to $30 million within five years. The plant-based ingredient company is winning business across detergent brands in both Europe and North America. IXICO (LSE:IXI, OTC:PHYOF, FRA:PY

Chesnara PLC (LSE:CSN) CEO Steve Murray talked with Proactive's Stephen Gunnion about the company’s transformational progress following two major acquisitions and what investors can expect next. Murray explained how these deals significantly increase the group’s scale, with a “material increase in the size of the balance sheet” and around £1 billion in expected lifetime cash flows. He highlighted that this strengthens long-term capital generation and supports Chesnara’s dividend strategy. The discussion also covered the integration process following the HSBC Life (UK) deal, including data qual

Chesnara (LON:CSN) used its full-year 2025 results presentation to highlight a year of strong operating performance alongside what management described as a “major period of strategic transformation,” including the completion of its largest-ever acquisition and continued growth in dividends. Strate

Chesnara (LSE:CSN) has had a busy few months — completing its HSBC Life acquisition and buying Scottish Widows Europe, backed by a £290 million capital raise. Full-year 2025 profits jumped 42% and the solvency ratio hit 257%, with the CEO saying there's more deal flow to come. Itaconix (AIM:ITX, OTCQB:ITXXF, FRA:18G0) has hit revenues of $10.5 million for the first time, up 61%, and is now forecasting its first positive EBITDA this year. The plant-based polymer company is winning business across North American detergent brands and opening up new ecommerce channels. Foresight Solar Fund Ltd (LS

Chesnara PLC (LSE:CSN) is buying Scottish Widows Europe for €110 million, targeting €250 million in lifetime cash. CEO Steve Murray says around €100 million should come in the first five years, supporting dividends. Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z) says automotive royalties are accelerating ahead of new EU safety rules. Management expects positive adjusted EBITDA in the third quarter, with no need to raise fresh capital. Seraphim Space Investment Trust PLC (LSE:SSIT) has seen a strong portfolio revaluation driven by defence contracts. CEO Mark Boggett says major funding rounds

Lloyds Banking Group (LSE:LLOY) has agreed to sell Scottish Widows Europe to Chesnara PLC. The deal marks Lloyds' exit from this closed life insurance business and Chesnara's entry into the Luxembourg market. Lloyds Banking Group, best known for its UK retail and commercial banking focus, has been refining its mix of businesses over several years. The sale of Scottish Widows Europe fits with that direction, concentrating the group more tightly on core activities while a specialist life...

Chesnara PLC (LSE:CSN) CEO Steve Murray talked with Proactive's Stephen Gunnion about the company’s €110 million acquisition of Scottish Widows Europe and why the deal is expected to generate approximately €250 million in lifetime cash. Murray explained that lifetime cash generation remains a core attraction in Chesnara’s acquisition strategy. Of the €250 million expected from the transaction, around €100 million is forecast within the first five years, supporting early capital return alongside long-term cash flow sustainability. He noted that the deal marks Chesnara’s 16th acquisition in arou

Chesnara PLC (LSE:CSN) is buying Scottish Widows Europe from Lloyds Banking Group for €110 million in cash. The deal adds €1.7 billion of assets and is expected to generate €250 million of lifetime cash. Empire Metals Ltd (AIM:EEE, OTCQB:EPMLF) has launched its biggest drilling campaign yet at the Pitfield project in Western Australia. More than 750 holes are planned as it looks to upgrade and expand its titanium resource. Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) highlighted momentum in Zambia in its full-year results statement, following a new copper-silver discovery at Mushima Nor